BioTechGrid

Scientists Observe Enzymes Breaking Down DNA in Real Time

September 28, 2026

The Kanazawa University experiments revealed how the physical organization of DNA can protect it from degradation. [Just_Super/Getty Images] Researchers at…

Biotechnology

Roche drops muscle-sparing obesity antibody after flunked interim analysis

September 28, 2026

Roche has slammed the brakes on an obesity antibody after the candidate showed little hope of hitting its endpoints in…

Biotechnology

Mirum posts phase 3 hepatitis win for ‘commercially differentiated’ challenger to Gilead, Vir

September 28, 2026

A phase 3 trial of Mirum Pharmaceuticals’ chronic hepatitis delta virus drug candidate has hit its primary endpoint, furthering the biotech’s…

Biotechnology

Scynexis bags $214M BARDA contract for antifungal development

September 28, 2026

The Biomedical Advanced Research and Development Authority (BARDA) has awarded Scynexis with a $214 million contract for development of a treatment…

Biotechnology

Tolerance continues thymus-focused deals with $560M pact for Tanabe’s clinical-stage IL-33 drug

September 28, 2026

After vaulting into the clinic by licensing a fusion protein last month, Tolerance Bio has continued to strengthen its thymus-focused…

Genetics

Viral Protein Helps Self-Amplifying RNA Overcome Cellular Defenses

September 28, 2026

mRNA molecule, illustration. [Kateryna Kon/Science Photo Library/Getty Images] A new study led by scientists at Queen Mary University of London…

Medical Technology

Precision Neuroscience taps $250M in Series D funding for brain-computer interface

September 28, 2026

Precision Neurosciences, which specializes in brain-computer interface technology, raised $250 million in an oversubscribed Series D financing round.

Biotechnology

Kodiak’s stock doubles as resurrected eye disease drug matches Eylea in phase 3

September 28, 2026

Two of Kodiak Sciences’ drug candidates have matched Eylea in a phase 3 clinical trial, positioning the biotech to seek FDA…

Biotechnology

Merck pens $2.1B deal with China’s SciBrunch to chase KRAS G12D

September 28, 2026

Merck & Co. has become the latest pharma to jump on the KRAS G12D bandwagon, paying $400 million to China’s…

Medical Technology

VC Sofinnova reels in €82M to target medtechs in the next 5 years

September 28, 2026

Sofinnova Partners has hauled in 82 million euro ($93.3 million) in an oversubscribed financing round. The European venture capital group…

Scientists Observe Enzymes Breaking Down DNA in Real Time

Roche drops muscle-sparing obesity antibody after flunked interim analysis

Mirum posts phase 3 hepatitis win for ‘commercially differentiated’ challenger to Gilead, Vir

Scynexis bags $214M BARDA contract for antifungal development

Tolerance continues thymus-focused deals with $560M pact for Tanabe’s clinical-stage IL-33 drug

Viral Protein Helps Self-Amplifying RNA Overcome Cellular Defenses

Exploring the Future of Healthcare with Panos Karelis

Exploring the Future of Healthcare with Gordon Wishart, Check4Cancer

Exploring the Future of Healthcare with Noam Shomron, Tel Aviv University

Exploring the Future of Healthcare with Raul Villamarin Rodriguez, Woxsen University

Scientists Observe Enzymes Breaking Down DNA in Real Time

Roche drops muscle-sparing obesity antibody after flunked interim analysis

Mirum posts phase 3 hepatitis win for ‘commercially differentiated’ challenger to Gilead, Vir

Scynexis bags $214M BARDA contract for antifungal development

Tolerance continues thymus-focused deals with $560M pact for Tanabe’s clinical-stage IL-33 drug

Viral Protein Helps Self-Amplifying RNA Overcome Cellular Defenses

Precision Neuroscience taps $250M in Series D funding for brain-computer interface

Kodiak’s stock doubles as resurrected eye disease drug matches Eylea in phase 3

Merck pens $2.1B deal with China’s SciBrunch to chase KRAS G12D

VC Sofinnova reels in €82M to target medtechs in the next 5 years

Precision Neuroscience taps $250M in Series D funding for brain-computer interface

VC Sofinnova reels in €82M to target medtechs in the next 5 years

Adagio Medical kicks off strategic review, trims more than half its staff

Grail survives adcomm vote as it awaits FDA decision for cancer blood test